The content on this site is intended for healthcare professionals only
Dr John DiPersio speaks to ecancer about his work on the use of CARTs for the treatment of T-cell ALL and T-cell non-hodgkin lymphoma.
He gives a thorough explanation of the development of this treatment, from conception through to development and manufacture.
Dr DiPersio explains how some of the potential complications of this process can be overcome, and looks forward to the human trial stage of this process.
Hopefully, this treatment will be available later this year, and the research will be expanded to later tackle AML.
Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results
Understanding the remaining unmet needs in a post ASCT NDMM setting
Approaches to risk stratification in high risk myeloma
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
ASCO 2024: Lung cancer highlights
